The upper GI studies focus on non-steroidal anti-inflammatory drugs (NSAID) induced ulceration (a multi-factorial disease) where we have identified a novel mechanistic pathway that perturbs cell survival. For lower GI toxicity, our focus is on anti-cancer medicines, including conventional chemotherapeutics, kinase inhibitors, and immune checkpoint inhibitors - all of which are associated with significant incidences of diarrhoea and colitis.
This research theme utilises cellular (including gastroids and enteroids), endoscopic, imaging and patient studies, along with the use of UK biobank (where appropriate) to understand the fundamental mechanisms of the adverse drug reactions (ADRs).
We have built a valuable resource through recruitment of deeply phenotyped patients and we will expand this resource (particularly in the lower GI area) through collaboration with cancer centres.
CDSS investigators
Back to: Centre for Drug Safety Science
